British Biosimilars Association launches in UK
New industry body the British Biosimilars Association (BBA) has officially launched in the UK.
The British Generic Manufacturers Association (BGMA) released a statement yesterday, April 18, where it outlined what the body’s core focus will be.
The BBA is an expert sector group of the BGMA and is focused on biosimilar medicines. Its focus will be on ensuring patients can benefit from these medicines to the “same extent” as those in Europe.
According to the BGMA, the UK is currently lagging behind some European countries in the take-up of biosimilar medicines.
The BGMA also said that “restricting patient access to these medicines costs the National Health Service money” that could be used for other treatments.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk